Person: COŞKUN, BELKIS NİHAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
COŞKUN
First Name
BELKIS NİHAN
Name
24 results
Search Results
Now showing 1 - 10 of 24
Publication General characteristics of male breast cancer patients in Bursa region(Aves, 2012-07-01) Avcı, Nilüfer; Balcı, Mehmet Ali; Esen, İrfan; Tandoğan, Gülen; Merter, Mustafa; Çubukcu, Erdem; Ölmez, Fatih; Coşkun, Belkıs Nihan; Hartavi, Mustafa; Tolunay, Şahsine; Avcı, Nilüfer; Balcı, Mehmet Ali; Esen, İrfan; Tandoğan, Gülen; Merter, Mustafa; ÇUBUKÇU, ERDEM; Ölmez, Fatih; COŞKUN, BELKIS NİHAN; Hartavi, Mustafa; TOLUNAY, ŞAHSİNE; Uludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0003-1465-7153; AAI-1612-2021; ABD-7124-2020; AAG-7155-2021; ABI-4413-2020; CCT-7946-2022; DYT-8587-2022; DFP-9003-2022; JGT-4101-2023; JGV-7746-2023; CUI-5353-2022Introduction: Male breast cancer constitutes less than 1% of all cases of breast cancer. In this study, we analyzed clinical and pathological features of male breast cancer cases, which had been followed up and treated at our institution.Material and Method: The data regarding the main clinicopathological features of the male breast cancer patients were retrieved from the patients' records retrospectively.Results: A total of 16 patients were included in the analysis with a median age of 60 (41-75). The most common cell type was infiltrating ductal carcinoma, comprising 81.3 % of all cases. Most patients were staged as locally advanced (50% - stage 3) at the time of diagnosis. Estrogen and/or progesterone receptor positivity were found in 13 patients (81.3%). HER2 status could be examined in 9 patients, and 4 patients (25%) found to be positive for HER2 overexpression. Overall survival was 3(1-12) years and disease-free survival was 2 (1-8) years.Discussion: Despite the increasing knowledge about breast cancer in women, little is known in case of male breast cancer management. Therefore, there is a strong need to perform randomized studies for the treatment of male breast cancer.Publication Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability(Springer London, 2021-03-11) Topcu, Atakan; Mursaloğlu, H. Hakan; Yalcınkaya, Yasemin; Karakurt, Sait; Yağız, Burcu; Alaca, Zeynep; Demir, Meryem; Coşkun, Belkıs Nihan; Dalkılıç, Ediz; İnanç, Nevsun; YAĞIZ, BURCU; COŞKUN, BELKIS NİHAN; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; 0000-0002-0624-1986; 0000-0001-8645-2670; JQW-5031-2023; AAG-7155-2021; CMF-4757-2022Objectives We aim to investigate the relationship between pulmonary function and imaging parameters with symptom-related patient-reported outcome measures (PROs). Method We included 65 patients of rheumatoid arthritis (RA) and connective tissue disease (CTD) with and without interstitial lung disease (ILD) into this cross-sectional study. We evaluated the relationship between FVC, DLco, and PROs and compared to HRCT findings. PROs included visual analogue scale for breathing, modified Borg scale, medical research council dyspnea scale, St. George's respiratory questionnaire (SGRQ), Leicester cough questionnaire, and Short Form 36 quality of life (SF-36 QoL). Results The mean age was 57.4 +/- 9.7 and 61.9% (39/65) of patients had an established ILD. In RA-ILD group, SGRQ score was higher (p < 0.001) and SF-36 physical functioning score was lower (p = 0.02) than CTD-ILD group. In RA group, there was a significant correlation between FVC and SF-36 role functioning/physical score (r = 0.724, p = 0.012). In CTD group, SF-36 general health score was correlated with both FVC (r = 0.441, p = 0.045) and DLco (r = 0.485, p = 0.035), and also SF-36 physical functioning score was correlated with FVC (r = 0.441, p = 0.040). PROs were found to be similar between ILD and non-ILD patients. SF-36 QoL total and SGRQ outcomes were worse in non-ILD group. Conclusions We concluded that PROs could be used to evaluate health-related quality of life (HRQoL) in RA- or CTD-related ILD. The physical health determinants of HRQoL are measurably worse in RA-ILD patients than in CTD patients. But, PROs may not be very helpful in differentiating patients with cough and/or shortness of breath due to ILD or non-ILD causes in RA/CTD.Publication Fatal cryptococcal meningitis in a patient with chronic lymphocytic leukemia(Pagepress Publ, 2012-01-01) Dizdar, Oğuzhan Sıtkı; Karakeçili, Faruk; Coşkun, Belkıs Nihan; COŞKUN, BELKIS NİHAN; Ener, Beyza; ENER, BEYZA; Ali, Rıdvan; ALİ, RIDVAN; Mistik, Reşit; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı.; D-6213-2013; AAG-8523-2021; AAG-7155-2021Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections, especially opportunistic infections. We have described a patient with CLL who had cryptococcal meningitis. Despite lack of previous immunosuppressive treatment history, the patient experienced serious and fatal fungal infection. Physicians should be alert for a diagnosis of cryptococcal meningitis in patient with CLL who developed fever and headache.Publication The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment(Termedia Publishing House Ltd, 2019-01-01) Coşkun, Belkıs Nihan; Dizdar, Oğuzhan Sıtkı; Korkmaz, Seniz; Ulukaya, Engin; Evrensel, Türkkan; COŞKUN, BELKIS NİHAN; Korkmaz, Seniz; Ulukaya, Engin; EVRENSEL, TÜRKKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Biyokimya Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0003-0298-4157 ; 0000-0001-5779-9499; 0000-0003-4875-5472; 0000-0002-9732-5340; AAG-7155-2021; HTN-1234-2023; K-5792-2018; AAJ-1027-2021Aim of the study: To investigate the efficacy of evaluating prognosis and response to lung cancer treatment using M30 and M65 antigens, which are indicators of necrosis.Material and methods: Forty-eight patients with lung cancer, who were planned to receive neoadjuvant chemotherapy, and 38 healthy volunteers were enrolled in the study. Using M30 and M65 levels, cytokeratin 18 levels were measured twice: before and 48 hours after the first chemotherapy treatment. Apoptotic and total necrosis levels were determined by measuring the M65 and M30 levels.Results: The M30 and M65 antigen levels in the patient group were significantly higher than in the control group (p < 0.001). The M30 and M65 antigen levels were significantly higher 48 hours after the chemotherapy compared with before the chemotherapy (p < 0.001). There were no significant differences in M65 levels between patients who responded to treatment and patients who progressed. The M30 levels increased significantly in patients with disease progression (p = 0.694 and p = 0.024, respectively). No significant differences in serum M30 and M65 antigen levels were found when compared between the surviving and deceased patients (p = 0.126 and p = 0.340, respectively).Conclusions: A significant increase was detected in serum M30 and M65 levels in patients with lung cancer. There was a greater increase in serum M30 levels in patients who did not respond to the chemotherapy. This result gives rise to the thought that evaluating apoptosis and total necrosis through M30 and M65 measurements alone only in patients receiving neoadjuvant chemotherapy would be insufficient for specifying the effectiveness of the treatment.Publication Are there any clues to predict bamboo spine in axial spondyloarthritis?(Wiley, 2020-10-01) Atagündüz, Pamir; Kiraz, Sedat; Akar, Servet; Küçükşahin, Orhan; Erden, Abdulsamet; Beş, Cemal; Kılıç, Levent; Karadağ, Ömer; Kaşifoğlu, Timuçin; Emmüngil, Hakan; Çınar, Muhammet; Kimyon, Gezmis; Yazısız, Veli; Ateş, Aşkın; Ersözlü, Emine Duygu; Gonullu, Emel; Mercan, Rıdvan; Ertenli, İhsan; Kalyoncu, Umut; Yağız, Burcu; YAĞIZ, BURCU; Coşkun, Nihan; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; CLH-7318-2022Publication Characteristics of patients who received biological treatment after kidney transplantation and the incidence of serious infections: A multicenter study(Bmj Publishing Group, 2023-06-01) Yıldırım, T. Demirci; Kökoğlu, E. Oğuz; Coşkun, B. N.; Yıldırım, D.; Şenel, S.; Pehlivan, Y.; Küçük, H.; Kaşifoğlu, T.; Sarı, I.; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; KIW-0794-2024; FQP-0451-2022Publication Irritable bowel syndrome in patients on renal replacement treatment(Oxford Univ Press, 2015-05-01) Aktaş, Nimet; Oruç, Ayşegül; Ersoy, Alparslan; Coşkun, Belkıs Nihan; Gül, Bülent; Yıldız, Abdulmecit; Ayar, Yavuz; Sayılar, Emel Işıktaş; Aktaş, Nimet; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; COŞKUN, BELKIS NİHAN; GÜL, CUMA BÜLENT; YILDIZ, ABDULMECİT; Ayar, Yavuz; Sayılar, Emel Işıktaş; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0002-0710-0923; 0000-0003-0298-4157; AGF-0767-2022; AAH-4002-2021; AAH-5054-2021; O-9948-2015; AAG-7155-2021; GSE-0029-2022; W-2575-2017Publication An observational study from the perspective of rheumatology in the management of patients with psoriatic arthritis in Turkey - LOOP study(Wiley, 2021-09-01) Dalkılıç, Ediz; Solmaz, Dilek; Küçükşahin, Orhan; Çapkın, Erhan; Derin, Mehmet Emin; Arslan, Didem; Noyan, Fatih; Coşkun, Nihan Belkıs; Murat, Sadiye; Şendur, Ömer Faruk; Melikoğlu, Meltem Alkan; Gürsoy, Savaş; Kaya, Taciser; Şahin, Ali; Karkucak, Murat; Pırıldar, Timur; Terzioğlu, Mustafa Ender; Beş, Cemal; Akar, Servet; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; CMF-4757-2022; ICV-9647-2023Publication Methotrexate intoxication: Beyond the adverse events(Clinical & Exper Rheumatology, 2018-01-01) Dalkılıç, Ediz; Coşkun, Belkıs Nihan; Yağız, Burcu; Ermurat, Selime; Tufan, Ayşe Nur; Pehlivan, Yavuz; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; Ermurat, Selime; Tufan, Ayşe Nur; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bölümü; 0000-0003-0298-4157; AAG-7155-2021; JQW-5031-2023; ABE-4424-2022; AAG-8227-2021; CMF-4757-2022; GHE-4236-2022Publication Leflunomide as a concomitant dmard choice for the biological treatment era of rheumatoid arthritis(Wiley, 2018-09-01) Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Beş, Cemal; Kanitez, Nilüfer Alpay; Kaşifoğlu, Timuçin; Emmungil, Hakan; Coşkun, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Askin; Akar, Servet; Bakırlı, Duygu Ersözlü; Yazısız, Veli; Bilge, Nazife Şule Yaşar; Tufan, Müge Aydın; Mercan, Rıdvan; Karadağ, Ömer; Keleşoğlu, Ayşe Bahar; Gercik, Onay; Öz, Burak; Akar, Zeynel Abidin; Yılmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Şükran; Tekgöz, Emre; Taşçılar, Koray; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; YAĞIZ, BURCU; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Ramotoloji Bölümü; 0000-0003-0298-4157; JQW-5031-2023; AAG-7155-2021; AAG-8227-2021; CMF-4757-2022
- «
- 1 (current)
- 2
- 3
- »